A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)

NCT04729907 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

115

Enrollment

INDUSTRY

Sponsor class

Conditions

Muscular Atrophy, Spinal

Interventions

DRUG: Nusinersen

Sponsor

Biogen